GlassScriptPhysician profile
Craig Wayne Patton
NPI 1750008728
$3,290.18
in general payments reported to CMS, 2019-2025
21 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $145 · 2023: $970 · 2024: $1,118 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,096 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,096.08 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $914.70 | 2022-2025 | Caplyta |
| Abbvie INC. | $434.20 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $268.38 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $263.85 | 2023-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $215.49 | 2022-2024 | Azstarys |
| Alkermes, INC. | $200.15 | 2023-2024 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $142.48 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Noven Therapeutics, LLC | $136.44 | 2023-2025 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $105.84 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $95.80 | 2022-2025 | Auvelity |
| Lundbeck LLC | $81.25 | 2023-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $70.67 | 2023-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $63.52 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.90 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $47.67 | 2022-2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $45.32 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $41.25 | 2023-2025 | Trintellix |
| Tris Pharma INC | $38.18 | 2025 | Dyanavel Xr, Onyda Xr |
| Vanda Pharmaceuticals INC. | $37.94 | 2024 | Fanapt |
| Avion Pharmaceuticals | $20.90 | 2023 | Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $16.25 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.